Prussian blue (PB), a kind of ferrous ferricyanide composed of Fe2+ and Fe3+, has been approved by Food and Drug Administration (FDA, USA) as an oral drug for the treatment of thallium and cesium poisoning. The biosafety of PB has been proved by long-term clinical trials. In recent years, PB nano-materials have attracted intensive research interests for medical application, especially for tumor imaging and treatment of cancer. Compared to other nano-materials, PB has potential advantage in medical application due to the high biosafety. This paper reviews the new advances in the functions of cancer diagnosis and therapy of PB nano-materials.
Cuproptosis, recently defined as a unique form of cell death distinct from programmed cell death, is triggered by copper overload within mitochondria. Genes associated with cuproptosis have been found to correlate with tumorigenesis and tumor progression, making the targeting of cuproptosis pathways a promising direction for anti-tumor therapies. Copper ion carriers can transport copper ions into cells, inducing cuproptosis and laying the foundation for its application in cancer treatment. This article elaborates on the homeostasis of copper and the mechanisms related to cuproptosis, further clarifying the relationship between cuproptosis and lung cancer treatment targets. This review aims to summarize current progress in research related to cuproptosis and lung cancer, providing new theories and bases for the clinical treatment of lung cancer.
